Part 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Source last updated 2026-05-18
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
Score on a Scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 19, 20, 21, 22, 23, 24, 27, 30, 33, 36, 39, 40, 42, 45, 48, 51, 54, 57, 60, 63, 66; Follow-up visit 1 (14 to 30 days after last study treatment) then continued follow-up every 3 months
What was measured
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
Analysis population: Includes only participants in part 1 with both baseline and at least one post-baseline value. Overall number of participants analysed = participants evaluable for the outcome measure. Number analyzed = participants evaluable at the specified timepoint
Groups in this outcome
Part 1: Cemiplimab + Chemotherapy
Participants received cemiplimab plus platinum-based doublet chemotherapy
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
Part 1: Chemotherapy
Participants received platinum-based doublet chemotherapy
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
97
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
102
Part 1: Chemotherapy
91
Reported measurements
Cycle 2, Day 1 (C2D1)
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
94
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
100
Part 1: Chemotherapy
91
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
2.13
17.237
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
1.58
15.154
Not reported
Not reported
Not reported
Part 1: Chemotherapy
0.92
14.930
Not reported
Not reported
Not reported
C3D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
86
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
97
Part 1: Chemotherapy
85
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
4.65
16.598
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
2.75
18.310
Not reported
Not reported
Not reported
Part 1: Chemotherapy
2.16
16.525
Not reported
Not reported
Not reported
C4D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
83
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
89
Part 1: Chemotherapy
75
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
6.22
16.505
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
3.00
20.383
Not reported
Not reported
Not reported
Part 1: Chemotherapy
2.67
17.446
Not reported
Not reported
Not reported
C5D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
78
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
83
Part 1: Chemotherapy
52
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
3.31
19.385
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
4.72
18.414
Not reported
Not reported
Not reported
Part 1: Chemotherapy
0.32
18.957
Not reported
Not reported
Not reported
C6D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
71
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
74
Part 1: Chemotherapy
49
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
5.63
19.302
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
3.38
19.356
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-1.70
20.552
Not reported
Not reported
Not reported
C9D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
57
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
51
Part 1: Chemotherapy
11
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
6.87
17.965
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
1.80
22.005
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-3.79
16.399
Not reported
Not reported
Not reported
C12D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
45
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
41
Part 1: Chemotherapy
7
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
4.44
22.019
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
9.15
20.650
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-3.57
13.486
Not reported
Not reported
Not reported
C15D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
34
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
39
Part 1: Chemotherapy
6
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
7.35
24.769
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
9.40
19.325
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-5.56
13.608
Not reported
Not reported
Not reported
C18D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
26
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
30
Part 1: Chemotherapy
5
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
6.73
25.606
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
14.44
20.983
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-3.33
13.944
Not reported
Not reported
Not reported
C19D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
7
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
8
Part 1: Chemotherapy
2
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
22.62
20.250
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
4.17
18.898
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-16.67
0.000
Not reported
Not reported
Not reported
C20D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
6
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
7
Part 1: Chemotherapy
2
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
13.89
26.176
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
9.52
12.199
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-16.67
0.000
Not reported
Not reported
Not reported
C21D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
22
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
26
Part 1: Chemotherapy
4
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
11.36
24.336
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
15.71
20.592
Not reported
Not reported
Not reported
Part 1: Chemotherapy
0.00
13.608
Not reported
Not reported
Not reported
C22D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
5
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
7
Part 1: Chemotherapy
1
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
20.00
29.226
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
5.95
9.272
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-16.67
Not reported
Not reported
Not reported
Not reported
C23D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
5
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
4
Part 1: Chemotherapy
2
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
11.67
26.745
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
12.50
4.811
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-8.33
11.785
Not reported
Not reported
Not reported
C24D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
18
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
21
Part 1: Chemotherapy
3
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
8.33
26.040
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
14.29
23.295
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-11.11
9.623
Not reported
Not reported
Not reported
C27D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
15
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
21
Part 1: Chemotherapy
3
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
8.89
24.694
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
19.05
18.285
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-22.22
41.944
Not reported
Not reported
Not reported
C30D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
16
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
22
Part 1: Chemotherapy
3
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
10.94
25.408
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
13.64
17.918
Not reported
Not reported
Not reported
Part 1: Chemotherapy
-5.56
19.245
Not reported
Not reported
Not reported
C33D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
13
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
20
Part 1: Chemotherapy
2
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
12.82
19.429
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
14.17
17.543
Not reported
Not reported
Not reported
Part 1: Chemotherapy
0.00
23.570
Not reported
Not reported
Not reported
C36D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
8
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
17
Part 1: Chemotherapy
1
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
12.50
22.713
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
13.24
17.936
Not reported
Not reported
Not reported
Part 1: Chemotherapy
16.67
Not reported
Not reported
Not reported
Not reported
C39D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
1
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
Part 1: Chemotherapy
16.67
Not reported
Not reported
Not reported
Not reported
C40D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
C42D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
1
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
Part 1: Chemotherapy
16.67
Not reported
Not reported
Not reported
Not reported
C45D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
C48D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
C51D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
50.00
Not reported
Not reported
Not reported
Not reported
C54D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
33.33
Not reported
Not reported
Not reported
Not reported
C57D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
33.33
Not reported
Not reported
Not reported
Not reported
C60D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
33.33
Not reported
Not reported
Not reported
Not reported
C63D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
33.33
Not reported
Not reported
Not reported
Not reported
C66D1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
0
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
41.67
Not reported
Not reported
Not reported
Not reported
Follow-up 1
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
35
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
53
Part 1: Chemotherapy
56
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
4.05
18.455
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
3.14
21.260
Not reported
Not reported
Not reported
Part 1: Chemotherapy
3.87
20.839
Not reported
Not reported
Not reported
Follow-up 2
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
2
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
1
Part 1: Chemotherapy
13
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
8.33
11.785
Not reported
Not reported
Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
33.33
Not reported
Not reported
Not reported
Not reported
Part 1: Chemotherapy
3.21
22.704
Not reported
Not reported
Not reported
Follow-up 3
Analysis denominator · Participants
Group
Source count
Part 1: Cemiplimab + Chemotherapy
1
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
0
Part 1: Chemotherapy
2
Values in Score on a Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Cemiplimab + Chemotherapy
-8.33
Not reported
Not reported
Not reported
Not reported
Part 1: Chemotherapy
4.17
5.893
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
17.237
value
2.13
group Id
OG001
spread
15.154
value
1.58
group Id
OG002
spread
14.930
value
0.92
denoms
counts
group Id
OG000
value
94
group Id
OG001
value
100
group Id
OG002
value
91
units
Participants
title
Cycle 2, Day 1 (C2D1)
categories
measurements
group Id
OG000
spread
16.598
value
4.65
group Id
OG001
spread
18.310
value
2.75
group Id
OG002
spread
16.525
value
2.16
denoms
counts
group Id
OG000
value
86
group Id
OG001
value
97
group Id
OG002
value
85
units
Participants
title
C3D1
categories
measurements
group Id
OG000
spread
16.505
value
6.22
group Id
OG001
spread
20.383
value
3.00
group Id
OG002
spread
17.446
value
2.67
denoms
counts
group Id
OG000
value
83
group Id
OG001
value
89
group Id
OG002
value
75
units
Participants
title
C4D1
categories
measurements
group Id
OG000
spread
19.385
value
3.31
group Id
OG001
spread
18.414
value
4.72
group Id
OG002
spread
18.957
value
0.32
denoms
counts
group Id
OG000
value
78
group Id
OG001
value
83
group Id
OG002
value
52
units
Participants
title
C5D1
categories
measurements
group Id
OG000
spread
19.302
value
5.63
group Id
OG001
spread
19.356
value
3.38
group Id
OG002
spread
20.552
value
-1.70
denoms
counts
group Id
OG000
value
71
group Id
OG001
value
74
group Id
OG002
value
49
units
Participants
title
C6D1
categories
measurements
group Id
OG000
spread
17.965
value
6.87
group Id
OG001
spread
22.005
value
1.80
group Id
OG002
spread
16.399
value
-3.79
denoms
counts
group Id
OG000
value
57
group Id
OG001
value
51
group Id
OG002
value
11
units
Participants
title
C9D1
categories
measurements
group Id
OG000
spread
22.019
value
4.44
group Id
OG001
spread
20.650
value
9.15
group Id
OG002
spread
13.486
value
-3.57
denoms
counts
group Id
OG000
value
45
group Id
OG001
value
41
group Id
OG002
value
7
units
Participants
title
C12D1
categories
measurements
group Id
OG000
spread
24.769
value
7.35
group Id
OG001
spread
19.325
value
9.40
group Id
OG002
spread
13.608
value
-5.56
denoms
counts
group Id
OG000
value
34
group Id
OG001
value
39
group Id
OG002
value
6
units
Participants
title
C15D1
categories
measurements
group Id
OG000
spread
25.606
value
6.73
group Id
OG001
spread
20.983
value
14.44
group Id
OG002
spread
13.944
value
-3.33
denoms
counts
group Id
OG000
value
26
group Id
OG001
value
30
group Id
OG002
value
5
units
Participants
title
C18D1
categories
measurements
group Id
OG000
spread
20.250
value
22.62
group Id
OG001
spread
18.898
value
4.17
group Id
OG002
spread
0.000
value
-16.67
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
8
group Id
OG002
value
2
units
Participants
title
C19D1
categories
measurements
group Id
OG000
spread
26.176
value
13.89
group Id
OG001
spread
12.199
value
9.52
group Id
OG002
spread
0.000
value
-16.67
denoms
counts
group Id
OG000
value
6
group Id
OG001
value
7
group Id
OG002
value
2
units
Participants
title
C20D1
categories
measurements
group Id
OG000
spread
24.336
value
11.36
group Id
OG001
spread
20.592
value
15.71
group Id
OG002
spread
13.608
value
0.00
denoms
counts
group Id
OG000
value
22
group Id
OG001
value
26
group Id
OG002
value
4
units
Participants
title
C21D1
denoms
counts
group Id
OG000
value
97
group Id
OG001
value
102
group Id
OG002
value
91
units
Participants
description
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
dispersion Type
Standard Deviation
groups
description
Participants received cemiplimab plus platinum-based doublet chemotherapy
id
OG000
title
Part 1: Cemiplimab + Chemotherapy
description
Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
id
OG001
title
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
description
Participants received platinum-based doublet chemotherapy
id
OG002
title
Part 1: Chemotherapy
param Type
MEAN
population Description
Includes only participants in part 1 with both baseline and at least one post-baseline value. Overall number of participants analysed = participants evaluable for the outcome measure. Number analyzed = participants evaluable at the specified timepoint
reporting Status
POSTED
time Frame
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 19, 20, 21, 22, 23, 24, 27, 30, 33, 36, 39, 40, 42, 45, 48, 51, 54, 57, 60, 63, 66; Follow-up visit 1 (14 to 30 days after last study treatment) then continued follow-up every 3 months
title
Part 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Triangle